0001209191-21-055072.txt : 20210907 0001209191-21-055072.hdr.sgml : 20210907 20210907191705 ACCESSION NUMBER: 0001209191-21-055072 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210902 FILED AS OF DATE: 20210907 DATE AS OF CHANGE: 20210907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pierce Christopher CENTRAL INDEX KEY: 0001824631 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39527 FILM NUMBER: 211240430 MAIL ADDRESS: STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED STREET 2: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: (302) 547-3768 MAIL ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-02 0 0001678660 Prelude Therapeutics Inc PRLD 0001824631 Pierce Christopher C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD WILMINGTON DE 19803 0 1 0 0 EVP and Chief of Business Oper Common Stock 2021-09-02 4 M 0 17000 12.85 A 20750 D Common Stock 2021-09-02 4 S 0 3343 40.2922 D 17407 D Common Stock 2021-09-02 4 S 0 6727 41.5176 D 10680 D Common Stock 2021-09-02 4 S 0 6930 42.4974 D 3750 D Employee Stock Option (right to buy) 12.85 2021-09-02 4 M 0 17000 0.00 D 2030-09-01 Common Stock 17000 207796 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. /s/ Brian Piper, Attorney-in-Fact 2021-09-07